LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB, Yonkus JA, Buckarma EH, Mun DG, Werneburg NW, Watkins RD, Alva-Ruiz R, Tomlinson JL, Guo Y, Wang J, O'Brien D, McCabe CE, Jessen E, Graham RP, Buijsman RC, Vu D, de Man J, Ilyas SI, Truty MJ, Borad M, Pandey A, Gores GJ, Smoot RL.
Conboy CB, et al. Among authors: buijsman rc.
J Hepatol. 2023 Jan;78(1):142-152. doi: 10.1016/j.jhep.2022.09.014. Epub 2022 Sep 24.
J Hepatol. 2023.
PMID: 36162702
Free PMC article.